APAX Partners

Paris, 17 June 2010 – The funds managed by Apax Partners SA, and Altamir Amboise, today sold their stake in the biotechnology company Galapagos, listed on Eurolist-C by Euronext Brussels and Amsterdam, namely 1,277,366 ordinary shares representing 5.4% of the company’s capital (including 76,641 shares for Altamir Amboise).

The shares were sold to European institutional investors. Kempen & Co from the Netherlands acted as placement agent to this transaction.

Hervé Descazeaux, Partner at Apax Partners, said: « Since we invested in this start-up in 2002, Galapagos has had an outstanding development through both its research programs and services activities. The company, which was listed in 2005, today has annual revenues in the excess of 100 million euros and alliances with the biggest players in the pharmaceutical industry. We feel proud to have contributed to this success. »

About Galapagos

Galapagos is a mid-size biotechnology company specialised in the discovery and development of small molecule and antibody therapies with novel modes-of-action. Galapagos has over 670 employees and operates facilities in six countries, with global headquarters in Mechelen, Belgium.
For additional information, see: www.glpg.com

About Apax Partners

Apax Partners SA is a leading private equity firm in France. With more than 30 years of investing experience, Apax Partners provides long-term equity financing to build and strengthen world-class companies.
Funds raised and managed by Apax Partners SA exceed €2 billion. These Funds invest in fast-growing companies across Apax’ sectors of specialisation: Technology, Telecom, Retail & Consumer, Media, Healthcare, Business & Financial Services.
For additional information, see: www.apax.fr

For further information, please contact:

Apax Partners SA
Agathe Heinrich - Communication Director
Tel.: +33 1 53 65 01 35
Email: agathe.heinrich@apax.fr